CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

Company Overview

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes. The company has assembled an intellectual property portfolio covering its lead compounds and key synthetic methods, positioning its programs for potential licensing or partnership opportunities that can support late-stage development and commercialization.

CNBX Pharmaceuticals’ management team brings together experts in pharmaceutical chemistry, clinical development and regulatory affairs to guide its programs through critical R&D milestones. As a clinical-stage enterprise, CNBX remains focused on advancing its lead assets toward first-in-human trials and forging strategic alliances to accelerate the delivery of next-generation cannabinoid-based therapies for patients with significant unmet medical needs.

Key Stats

• Today's Range: $0.0003 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.0002 to $0.0199
• Volume: 54.93 million shs
• Average Volume: 14.89 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNBX Stock Analysis - Frequently Asked Questions

How have CNBX shares performed this year?

CNBX Pharmaceuticals' stock was trading at $0.0074 at the beginning of 2025. Since then, CNBX shares have decreased by 95.9% and is now trading at $0.0003.

When did CNBX Pharmaceuticals' stock split?

CNBX Pharmaceuticals shares reverse split before market open on Thursday, May 12th 2022.The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram Global (OGI), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Curaleaf (CURLF), Cannabis Science (CBIS), KUSHCO (KSHB) and Trulieve Cannabis (TCNNF).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:CNBX
• CIK: 1343009
• Web: www.cannabics.com
• Phone: (877) 424-2429
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A